Connected Solution of Assistance Dedicated to Caregivers and People With Alzheimer's Disease or Related Diseases (Lili smart)
Lili Smart Study - Connected Solution of Assistance Dedicated to Caregivers and People With Alzheimer's Disease or Related Diseases
Alzheimer's disease and related diseases (ADRD) are a major public health issue. In France, nearly 900,000 people have ADRD, which represents about 70% of dementia cases, and the expected prevalence for 2020 is 1.2 million.
Patients with ADRD have cognitive, behavioral and functional impairments that lead to progressive impairment of quality of life and autonomy. Maintaining them at home depends predominantly on their caregivers, mainly family, spouse or child. By definition, the caregiver is "the person who provides partial or total support to an elderly dependent person or a person with a disability in the vicinity of the victim for the activities of daily life".
The investment of caregivers is therefore both human and financial, representing a greater or lesser burden. This burden can significantly affect their quality of life. Indeed, studies have shown that caregivers suffer from depletion, anxiety, depression and sleep disorders resulting in a deterioration of their health, leading them to greater care consumption. They would be more prone to cardiovascular diseases and cancer.
A review of the literature from 2009 examined 66 studies evaluating the contribution of various technologies targeting demented patients and their caregivers. Of these, only 10 dealt with independence at home and the well-being of the patient and his / her caregiver. The main limitations of these studies are the small samples (ranging from 1 to 6 patients), the degree of cognitive degradation (mainly moderately severe) and the lack of standardized assessment.
Although new technologies promise powerful home-based solutions, studies evaluating their efficacy for patients with ADRD and their caregivers remain scarce and fragile at the level of evidence due to methodological biases.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Description of the intervention: Lili Smart solution consists of an application for caregivers (web / mobile), a GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 / 24 and 7/7.
Objectives: The main objective is to evaluate the impact of the Lili Smart solution on the burden felt by caregivers of patients with ADRD at 3 months and at 6 months of follow-up.
The secondary objectives are to evaluate the impact of the Lili Smart solution at 3 months and 6 months of follow-up on:
- The anxiety of the caregiver of the patient with ADRD;
- Depression of the caregiver of the patient with ADRD;
- The quality of life of the caregiver of the patient with ADRD;
- The quality of life of the patient with ADRD,
- The level of functional autonomy of the patient with ADRD.
- The risks associated with the functional decline (falls, run aways) of the patient with ADRD.
In addition to the social impact measurement, the study aims to demonstrate the medico-economic impact of Lili smart solution as follow:
- The direct and indirect medical costs of the patient and the caregiver.
Patient and caregiver adherence to the Lili Smart solution will also be assessed as a secondary objective.
Methodology : This study is an interventional research on the human person meeting the definition 1 ° of article L1121-1 of the CSP and not relating to the products mentioned in article L. 5311-1 It is a randomized, controlled, single-blind, parallel-group, interventional, randomized, controlled trial in N = 60 patients and their primary caregiver with an observational phase (inactive device), and one interventional phase (activated device).
Tipo de estudio
Inscripción (Anticipado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Villeurbanne, Francia, 69100
- Reclutamiento
- Hopital des Charpennes
-
Contacto:
- Pierre Krolak Salmon, Pr
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
Caregiver inclusion's criteria :
- Natural caregiver helping the patient at least 6h / week for activities of daily living (if more than one caregiver, only one "referent" caregiver will be involved);
- Can be the caregiver of only one patient of the study.
- Having the ability to follow the study at the discretion of the investigator;
- Having agreed to participate in the study;
- Affiliated to a social security scheme;
Patient Inclusion Criteria:
- Diagnosis of Alzheimer's disease or related disease;
- Living at home
- Age ≥ 50 years
- Mini Mental State Examination (MMSE): 16-24 (included) (light to moderate);
- Affiliated to a social security scheme;
- Having agreed to participate in the study;
- Having the physical and psychic abilities to follow the study according to the appreciation of the investigator.
Exclusion Criteria:
Patients exclusion's criteria:
- Known psychiatric disorders
- Disabling motor and / or sensory impairment
- Patient under guardianship
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Functionalities of the Lili Smart Solution activated
Lili Smart solution consists of an application for caregivers (web / mobile), a GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 / 24 and 7/7.
|
Non-medical connected device (Lili Smart solution) activated : application for caregivers (web / mobile), GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 /24 and 7/7.
Otros nombres:
|
|
Otro: Functionalities of the Lili Smart Solution non activated
Lili Smart watch worn by the participants and sensors placed at home with their functionalities inactivated.
Absence of the web / mobile application.
|
Non-medical connected device (Lili Smart solution) with inactive functionalities : watch worn by the participants and sensors placed at home with their functionalities inactivated.
Absence of the web / mobile application.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Caregiver's burden evolution
Periodo de tiempo: 6 months after randomization
|
Natural caregiver's burden evolution after 6 months of follow-up.
Natural caregiver's burden evolution after 6 months of follow-up.
Assessement with the Zarit scale
|
6 months after randomization
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Evolution of the caregiver's anxiety level
Periodo de tiempo: 3 months and 6 months after randomization
|
Evolution of the caregiver's anxiety level estimated with repeated measures with the Spielberger's State-Trait Anxiety Inventory (STAI Y-A / Y-B).
|
3 months and 6 months after randomization
|
|
Evolution of the caregiver's depressive symptomatology
Periodo de tiempo: 3 months and 6 months after randomization
|
Evolution of the caregiver's depressive symptomatology estimated with repeated measures of the Beck Depression Inventory (BDI)
|
3 months and 6 months after randomization
|
|
Evolution of the caregiver's quality of life
Periodo de tiempo: 3 months and 6 months after randomization
|
Evolution of the caregiver's quality of life estimated with repeated measures of the Quality of Life in Alzheilmer's Disease scale, caregiver version
|
3 months and 6 months after randomization
|
|
Evolution of the patient's quality of life
Periodo de tiempo: 3 months and 6 months after randomization
|
Evolution of patient's quality of life estimated with repeated measures of the Quality of Life in Alzheilmer's Disease scale, patient version
|
3 months and 6 months after randomization
|
|
Evolution of the patient's independence
Periodo de tiempo: 3 months and 6 months after randomization
|
Evolution of the patient's independence with repeated measures of the Instrumental Activities of Daily Life (IADL-E, 9 items).
|
3 months and 6 months after randomization
|
|
Evolution of the caregiver's quality of life
Periodo de tiempo: 3 months and 6 months after randomization
|
Evolution of the caregiver's quality of life estimated with repeated measures of the Quality of Life with EQ-5D questionnaire (EuroQol Five Dimensions questionnaire).
|
3 months and 6 months after randomization
|
|
Evolution of the patient's quality of life
Periodo de tiempo: 3 months and 6 months after randomization
|
Evolution of patient's quality of life estimated with repeated measures of the Quality of Life with EQ-5D questionnaire (EuroQol Five Dimensions questionnaire).
|
3 months and 6 months after randomization
|
|
Number of falls
Periodo de tiempo: 1 months, 3 months and 6 months after randomization
|
Number of times the patient has fallen after 1 month, 3 months and 6 months.
|
1 months, 3 months and 6 months after randomization
|
|
Number of run aways
Periodo de tiempo: 1 months, 3 months and 6 months after randomization
|
Number of times the patient has ran away after 1 month, 3 months and 6 months.
|
1 months, 3 months and 6 months after randomization
|
|
Number of drugs prescribed to the caregiver and the patient
Periodo de tiempo: at inclusion and at 6 months
|
Evolution of the number of drugs prescribed to the caregiver and the patient at inclusion and after 6 months of follow-up.
|
at inclusion and at 6 months
|
|
Indirect medical costs and direct non-medical costs
Periodo de tiempo: 6 months
|
Data for indirect medical costs and direct non-medical costs will be collected with the RUD LITE questionnaire and the Lyon CMRR's MEMORA database
|
6 months
|
|
Evaluation of the caregiver's adherence to the Lili Smart solution
Periodo de tiempo: 7 months
|
Evaluation of the caregiver's adherence to the Lili Smart solution after 7 months of follow-up (1 month of observation phase then 6 months of intervention) estimated through data collected in Lili Smart databases (number of connections to the application).
|
7 months
|
|
Evaluation of patient's adherence to the Lili Smart solution
Periodo de tiempo: 7 months
|
Evaluation of the patient's adherence to the Lili Smart solution after 7 months of follow-up (1 month of observation phase then 6 months of intervention) estimated through data collected in Lili Smart databases (number of hours when the watch is worn).
|
7 months
|
|
Caregiver's burden evolution
Periodo de tiempo: 3 months after randomization
|
Natural caregiver's burden evolution after 3 months of follow-up.
Assessement with the Zarit scale
|
3 months after randomization
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Pierre Krolak-Salmon, MD, Hospices Civils de Lyon
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 69HCL16_0706
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Enfermedad de Alzheimer
-
ProgenaBiomeRetiradoEnfermedad de Alzheimer | Enfermedad de Alzheimer, inicio temprano | Enfermedad de Alzheimer, inicio tardío | Enfermedad de Alzheimer 1 | Enfermedad de Alzheimer 2 | Enfermedad de Alzheimer 3 | Enfermedad de Alzheimer 4 | Enfermedad de Alzheimer 7 | Enfermedad de Alzheimer 17 | Enfermedad de Alzheimer 5 | Enfermedad... y otras condicionesEstados Unidos
-
Cognito Therapeutics, Inc.Activo, no reclutandoDeterioro Cognitivo | Demencia | Enfermedad de Alzheimer | Defecto cognitivo leve | Deterioro cognitivo | Enfermedad de Alzheimer, inicio temprano | Enfermedad de Alzheimer, inicio tardío | ICM | Demencia alzhéimer | Demencia leve | Demencia de tipo Alzheimer | Deterioro Cognitivo, Leve | Enfermedad de Alzheimer 1 | Demencia leve y otras condicionesEstados Unidos
-
University of SaskatchewanCenter of Molecular Immunology, CubaAún no reclutandoEnfermedad de Alzheimer leve | Enfermedad de Alzheimer moderadaCanadá
-
Centre Hospitalier Universitaire de NiceTerminadoPaciente de Alzheimer preferencial | Paciente con Alzheimer Demencia | TestigoFrancia
-
Massachusetts Institute of TechnologyReclutamientoEnfermedad de Alzheimer | Enfermedad de Alzheimer, inicio temprano | Enfermedad de Alzheimer, inicio tardío | Enfermedad de alzheimer | Enfermedad de Alzheimer (incluidos los subtipos) | AlzheimerEstados Unidos
-
Stanford UniversityAún no reclutandoDCL con mayor riesgo de enfermedad de Alzheimer | Enfermedad de AlzheimerEstados Unidos
-
AphiosAún no reclutandoDemencia | Enfermedad de Alzheimer 1 | Enfermedad de Alzheimer 2 | Enfermedad de Alzheimer 3
-
Second Affiliated Hospital, School of Medicine,...Aún no reclutandoDemencia de Alzheimer | Enfermedad de Alzheimer (EA) | MCI-AD, enfermedad de Alzheimer en etapa tempranaPorcelana
-
Istanbul University - Cerrahpasa (IUC)Aún no reclutandoDemencia tipo Alzheimer | Enfermedad de alzheimer | Demencia de AlzheimerPavo
-
University of California, Los AngelesReclutamientoEnfermedad de Alzheimer | Demencia tipo Alzheimer | Alzheimer & amp;#39; s enfermedad (AD) | Enfermedad de Alzheimer | Enfermedad de Alzheimer leve | Enfermedad de Alzheimer moderada | Demencia de AlzheimerEstados Unidos